Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MET-CODCP 19 is a specialized oral nanoplatform consisting of metformin-bridged nanocochleates (MET-CO) optimized with dicetyl phosphate (DCP). This formulation was developed to repurpose metformin hydrochloride for the treatment of hepatocellular carcinoma (HCC), addressing the drug's high aqueous solubility and poor oral permeability. The nanocochleates are structured as uniform, snail-shaped nano-rolls that provide a controlled biphasic release profile over 24 hours. Preclinical studies demonstrate that MET-CODCP 19 significantly enhances the oral bioavailability of metformin (approximately 5.5-fold relative to standard solution) and exhibits potent anticancer activity by downregulating anti-apoptotic and cancer stemness genes in HepG2 cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MET-CODCP 19.